Life Couriers Completes Acquisition by JLL Partners and Appoints Edward DeMartini as CEO to Drive Global Healthcare Logistics Growth
Life Couriers, a global provider of time-critical healthcare logistics and transportation solutions, has completed its acquisition by JLL Partners, a New York-based middle-market private equity firm with a focus on healthcare, industrials and business services. Alongside the completion of the transaction, Life Couriers announced the appointment of Edward DeMartini as Chief Executive Officer, marking a new phase in the company’s growth strategy and global expansion.
DeMartini brings more than two decades of experience across specialty healthcare logistics, transportation and supply chain management. He succeeds Stefan Glebke, who will remain involved with Life Couriers as a strategic advisor to the company’s board of directors. His continued involvement is intended to support a smooth leadership transition and preserve the operational and strategic momentum established during his tenure.
The acquisition represents an important development for Life Couriers as demand continues to increase for specialized logistics services capable of transporting highly sensitive, valuable and time-critical healthcare products. With healthcare supply chains becoming increasingly complex, specialized logistics providers play a critical role in ensuring that medicines, biological materials and other healthcare products reach their intended destinations safely and within strict delivery windows.
Expanding Time-Critical Healthcare Logistics Capabilities
Headquartered in Munich, Germany, Life Couriers specializes in the transportation and handling of time-sensitive healthcare and life sciences materials. The company operates across six primary business segments: radiopharmaceuticals, life sciences, stem cell onboard services, direct-to-patient logistics, pharmaceutical freight and emergency logistics.
These specialized services address some of the most demanding requirements within the healthcare supply chain. Unlike conventional freight transportation, healthcare logistics often involves strict temperature requirements, regulatory controls, specialized packaging, chain-of-custody procedures and highly precise delivery schedules.
Radiopharmaceutical logistics is particularly time-sensitive because many radiopharmaceutical products have relatively short half-lives. Delays in transportation can therefore directly affect the usability of these products and potentially disrupt patient treatment schedules. Life Couriers’ specialized capabilities in this area position the company to support the growing use of nuclear medicine and radiopharmaceutical-based diagnostics and treatments.
The company also provides logistics solutions for life sciences materials, stem cell transportation and direct-to-patient healthcare delivery. These services are becoming increasingly important as healthcare providers, pharmaceutical companies and life sciences organizations move toward more decentralized treatment models.
Strategic Investment from JLL Partners
The acquisition by JLL Partners provides Life Couriers with access to the private equity firm’s healthcare industry expertise, financial resources and experience supporting middle-market companies.
JLL Partners focuses on investments across healthcare, industrials and business services, making Life Couriers a natural fit within its investment strategy. Through the transaction, Life Couriers expects to benefit from additional investment in its people, infrastructure and operations.
The company also intends to use the new ownership structure to strengthen its existing operations and pursue expansion opportunities in additional geographic markets. Life Couriers already has a presence across the United States, Europe, Central America and Asia, giving it a broad international operating footprint.
The company expects this geographic reach to become increasingly valuable as pharmaceutical and biotechnology companies continue to operate global supply chains and as demand for time-sensitive healthcare transportation increases.
JLL’s investment comes at a time when healthcare logistics is undergoing significant transformation. Pharmaceutical products are becoming more specialized, biologics and advanced therapies require increasingly controlled transportation environments, and healthcare delivery is moving closer to patients through decentralized and direct-to-patient models.
Edward DeMartini Takes Leadership Role
As part of the acquisition, Life Couriers appointed Edward DeMartini as its new Chief Executive Officer. DeMartini has more than 20 years of experience in global transportation, logistics and specialty healthcare supply chain services.
Before joining Life Couriers, DeMartini served as Chief Executive Officer of The Quick Group of Companies, a provider of global time-critical transportation and logistics services and a subsidiary of Kuehne + Nagel.
During his career, DeMartini has also held leadership and business development responsibilities at Kuehne + Nagel and DHL. His experience includes building international transportation networks, leading global teams and developing specialized logistics solutions for healthcare customers.
His background is particularly relevant to Life Couriers as the company seeks to expand its international presence while continuing to develop specialized solutions for highly time-sensitive healthcare products.
DeMartini said that joining Life Couriers provides an opportunity to lead a company focused on delivering critical healthcare materials during some of the most important moments in patients’ lives. He also emphasized the company’s broad service portfolio and its established position in radiopharmaceutical and time-critical healthcare logistics.
Under his leadership, Life Couriers plans to pursue growth in new geographic markets while strengthening its existing capabilities. The company will also continue focusing on radiopharmaceutical transportation and other specialized healthcare delivery services.
Increasing Demand for Radiopharmaceutical Logistics
One of the major growth opportunities for Life Couriers is the expanding radiopharmaceutical market. Radiopharmaceuticals are increasingly being used for both diagnostic imaging and targeted cancer treatment.
The development of new radioligand therapies and other nuclear medicine applications has increased the need for reliable logistics infrastructure capable of handling radioactive materials safely and efficiently.
Because these products can be highly time-sensitive, logistics providers must coordinate transportation carefully across manufacturers, specialized facilities, hospitals and treatment centers. Any disruption can create significant operational challenges.
Life Couriers has established expertise in this segment and intends to strengthen its position as demand for radiopharmaceutical logistics continues to rise. The company’s capabilities are designed to support pharmaceutical manufacturers, healthcare providers and other organizations involved in the development and delivery of nuclear medicine products.
Supporting Direct-to-Patient Healthcare Delivery
Another important area of opportunity is direct-to-patient logistics. The healthcare industry is increasingly moving away from traditional models in which patients must always visit hospitals or clinics to receive medicines and other healthcare services.
Home-based treatment, specialty pharmacy distribution and decentralized clinical care are contributing to demand for logistics solutions that can deliver healthcare products directly to patients while maintaining required handling and temperature conditions.
Life Couriers’ direct-to-patient services are designed to address these changing requirements. As pharmaceutical therapies become more personalized and complex, specialized delivery services may become increasingly important to ensuring patients receive their treatments on schedule.
The company’s combination of direct-to-patient capabilities and other specialized healthcare logistics services provides an opportunity to serve pharmaceutical and life sciences customers across multiple stages of the healthcare supply chain.
Leadership Transition Following Glebke’s Tenure
The appointment of DeMartini follows Stefan Glebke’s leadership of Life Couriers. Glebke played a key role in developing the company and integrating its operations into a broader global healthcare logistics platform.
Following the completion of the acquisition, Glebke will serve as a strategic advisor to the board. His continued participation is expected to help maintain continuity during the transition and support the company’s future strategic direction.
JLL Partners Managing Director Daniel Di Piazza, who also serves on the Life Couriers board of directors, recognized Glebke’s contributions while highlighting DeMartini’s experience in healthcare logistics and global transportation.
According to Di Piazza, the acquisition comes at a time when demand is increasing for specialized radiopharmaceutical and medical logistics services. He described DeMartini as an experienced executive with a history of scaling operations and developing solutions for complex supply chain challenges.
Positioned for Further International Expansion
With the acquisition now complete, Life Couriers enters its next stage of development with the backing of JLL Partners and new executive leadership.
The company plans to build upon its existing presence in the United States, Europe, Central America and Asia while exploring opportunities to enter additional markets. Geographic expansion will allow Life Couriers to support customers operating increasingly international healthcare supply chains.
The company’s strategy is expected to focus on strengthening its operational infrastructure, investing in employees, expanding specialized logistics capabilities and developing new customer solutions.
The combination of JLL’s healthcare investment expertise and Life Couriers’ specialized logistics platform could provide the foundation for further growth in a market where reliability, speed and regulatory compliance are essential.
A New Chapter for Life Couriers
The completion of the acquisition marks a significant milestone for Life Couriers and establishes a new platform for future expansion. With DeMartini taking over as CEO and Glebke continuing as a strategic advisor, the company is seeking to combine leadership continuity with new growth initiatives.
Life Couriers’ focus on radiopharmaceuticals, life sciences, stem cells, direct-to-patient services, pharmaceutical freight and emergency logistics places the company within a specialized segment of the global healthcare supply chain.
As pharmaceutical therapies become more sophisticated and healthcare delivery becomes increasingly decentralized, the need for secure, reliable and time-critical logistics is expected to remain strong. Life Couriers intends to capitalize on these trends by expanding its geographic reach and investing in the infrastructure and expertise required to serve healthcare customers worldwide.
The acquisition was completed by JLL Partners through the purchase of Life Couriers from an affiliate of AUCTUS Capital Partners, an investment firm focused on the European Mittelstand. With the transaction finalized, Life Couriers and JLL Partners will now focus on strengthening the company’s position as a global provider of specialized healthcare logistics while pursuing new opportunities in rapidly evolving areas such as radiopharmaceutical transportation and direct-to-patient healthcare delivery.
About Life Couriers
Life Couriers is an international group of specialized logistics service operators focused on life science and healthcare logistics. The group offers the broadest service portfolio on the market through six business segments: Radiopharma, Life Science, Stem Cell Onboard, Direct-to-Patient, Pharma Freight and Emergency Logistics. With strategic locations in the US, Europe, Central America and Asia, Life Couriers has a worldwide reach.
Life Couriers is operated by SLS Group GmbH and headquartered in Munich, Germany. More information at www.lifecouriers.com.
About JLL Partners
JLL Partners, LLC is a middle-market private equity firm with over three decades of experience transforming businesses in the healthcare, industrials, and business services sectors. The Firm is dedicated to partnering with companies that it believes it can help build into market leaders through a combination of organic growth initiatives, operational enhancements, and strategic acquisitions. The JLL Partners team is comprised of seasoned investment professionals and operating partners who are focused on driving long-term value creation across its portfolio. Since its founding in 1988, JLL Partners has invested approximately $9 billion of equity capital with 61 platform investments.